Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1999-01-07
1999-12-14
Degen, Nancy
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 231, 536 243, 435 911, 435375, 435 6, 435440, 514 44, C07H 2104, C07H 2102, A61K 4800, C12Q 1563, C12Q 168
Patent
active
060019921
ABSTRACT:
Compositions and methods are provided for modulating the expression of novel anti-apoptotic bcl-2-related proteins. Antisense oligonucleotides targeted to nucleic acids encoding the human novel anti-apoptotic bcl-2-related proteins A1 and mcl-1 are preferred. Methods of using these compounds for modulation of novel anti-apoptotic bcl-2-related protein expression and for treatment of diseases associated with expression of novel anti-apoptotic bcl-2-related proteins are also provided. Also provided are methods of using these compounds for promoting apoptosis and for treatment of diseases for which promotion of apoptosis is desired.
REFERENCES:
patent: 5583034 (1996-12-01), Green et al.
patent: 5646008 (1997-07-01), Thompson et al.
patent: 5776905 (1998-07-01), Gibbons et al.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 47-48, Feb. 1998.
Trisha Gura, Antisense Has Growing Pains, Science, pp. 575-577, Oct. 1995.
Stanley Crooke, Antisense '97: A roundtable on the state of the industry, Nature Biotechnology, p. 522, Jun. 1997.
Stanley Crooke, Antisense Research and Applications, Chapter 1, Basic Principles of Antisense Therapeutics, Springer-Verlag Press, Berlin, Heidelberg, New York, p. 3, Jul. 1998.
Uhlman et al., Antisense oligonucleotides: A New therapeutic principle, Chemical Reviews, vol. 90, No. 4, pp. 544-560, Jun. 1990.
Amarante-Mendes, et al., "Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-x.sub.1 ", Oncogene 1998 16, 1383-1390.
Chao, et al., "mcl-1 Is an Immediate Early Gene Activated by the Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Signaling Pathway and Is One Component of the Gm-CSF Viability Response", Mole. Cell. Biol. 1998 18, 4883-4898.
Fujio, et al., "Signals Through gp130 Upregulate bcl-x Gene Expression Via STAT1-binding cis-Element in Cardiac Myocytes", J. Clin. Invest. 1997 99, 2898-2905.
Pollman, et al., "Inhibition of neointimal cel bcl-x expression induces apoptosis and regression of vascular disease", Nature Med.1998 4, 222-227.
Wang, et al., "Induction of bcl-x by CD40 Engagement Rescues slg-Induced Apoptosis in Murine B Cells.sup.1 ", J. Immunol.1995 155, 3722-3725.
Ackermann Elizabeth J.
Bennett C. Frank
Dean Nicholas M.
Marcusson Eric G.
Degen Nancy
Epps Janet L
Isis Pharmaceuticals , Inc.
LandOfFree
Antisense modulation of novel anti-apoptotic bcl-2-related prote does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of novel anti-apoptotic bcl-2-related prote, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of novel anti-apoptotic bcl-2-related prote will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-864776